ASLAN Pharmaceuticals Ltd (ASLN), based in Singapore, is a biopharmaceutical innovator focused on developing advanced immunotherapy treatments for significant unmet needs in oncology and autoimmune diseases. The company has built a strong portfolio of clinical-stage candidates, reflecting its dedication to pioneering research that aims to significantly improve patient outcomes. With deep expertise in navigating the biopharmaceutical sector, ASLAN is well-positioned to capitalize on emerging market opportunities while delivering transformative therapies that address critical health challenges. Show more
Location: 3 TEMASEK AVENUE, SINGAPORE, SINGAPORE, 039190, 12 03 Ue Square, 239920, USA | Website: https://aslanpharma.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE
Market Cap
1.697M
52 Wk Range
$0.00 - $0.00
Previous Close
$0.60
Open
$0.60
Volume
N/A
Day Range
$0.60 - $0.60
Enterprise Value
0.00
Cash
18.4M
Avg Qtr Burn
N/A
Insider Ownership
0.14%
Institutional Own.
13.21%
Qtr Updated
03/31/24
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Eblasakimab (ASLAN004) (IL-13Ra1 inhibitor) Details Atopic dermatitis | Phase 2b Update | |
Farudodstat (ASLAN003) (DHODH inhibitor) Details Autoimmune disease, Alopecia areata | Phase 2a Data readout | |
Eblasakimab Details Atopic dermatitis | Failed Discontinued |